Published in Nature on August 11, 2005
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci U S A (2007) 3.93
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res (2007) 2.86
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell (2011) 2.40
Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32
PAK signalling during the development and progression of cancer. Nat Rev Cancer (2014) 2.21
Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS One (2007) 2.18
PAK signaling in oncogenesis. Oncogene (2009) 2.13
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid (2010) 2.05
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A (2010) 1.94
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation. EMBO J (2007) 1.74
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer (2009) 1.70
Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci U S A (2010) 1.70
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 1.57
Patient-oriented gene set analysis for cancer mutation data. Genome Biol (2010) 1.52
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology (2009) 1.50
Defining the blueprint of the cancer genome. Carcinogenesis (2008) 1.49
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
Akt: a double-edged sword in cell proliferation and genome stability. J Oncol (2012) 1.44
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene (2013) 1.40
The genomic landscape of response to EGFR blockade in colorectal cancer. Nature (2015) 1.39
Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet (2009) 1.39
Why sick cells produce tumors: the protective role of autophagy. Autophagy (2007) 1.34
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31
Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) (2011) 1.29
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol (2010) 1.27
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol (2010) 1.27
PAK signaling in cancer. Cell Logist (2012) 1.27
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev (2009) 1.26
Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis (2009) 1.23
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am (2008) 1.19
PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci (2010) 1.17
PTEN loss induces epithelial--mesenchymal transition in human colon cancer cells. Anticancer Res (2009) 1.17
The NF-κB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1β. Cancer Microenviron (2009) 1.13
Our changing view of the genomic landscape of cancer. J Pathol (2010) 1.13
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Phosphoproteomics in cancer. Mol Oncol (2010) 1.12
Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nat Med (2015) 1.11
Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov (2013) 1.10
Colorectal cancer. Nat Rev Dis Prim (2015) 1.07
P21 activated kinases: structure, regulation, and functions. Small GTPases (2014) 1.06
FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther (2008) 1.06
3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J Chem Biol (2009) 1.05
Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene (2013) 1.04
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer (2010) 1.04
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res (2007) 1.01
Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis (2010) 1.00
Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res (2008) 1.00
Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. Proc Natl Acad Sci U S A (2007) 0.98
IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol (2013) 0.98
New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens. Nucleic Acids Res (2012) 0.98
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci U S A (2006) 0.98
Cutaneous human papillomaviruses down-regulate AKT1, whereas AKT2 up-regulation and activation associates with tumors. Cancer Res (2007) 0.98
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One (2012) 0.97
Adipokines and obesity are associated with colorectal polyps in adult males: a cross-sectional study. PLoS One (2014) 0.97
3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia (2012) 0.96
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Mol Cell Biol (2011) 0.96
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem (2008) 0.96
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 0.95
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection. Int J Exp Pathol (2010) 0.95
Oncogenes come of age. Cold Spring Harb Symp Quant Biol (2005) 0.95
SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol (2011) 0.95
Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates. Clin Genet (2007) 0.94
Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol Cell Biol (2010) 0.93
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol (2008) 0.93
Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics. Mol Cell Proteomics (2013) 0.93
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med (2014) 0.93
Molecular markers for colorectal cancer screening. Gut (2015) 0.92
Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer (2014) 0.91
Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One (2013) 0.91
Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Dev Res (2009) 0.91
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics (2008) 0.91
Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep (2011) 0.91
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One (2012) 0.91
PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med (2013) 0.88
Inactivation of MARK4, an AMP-activated protein kinase (AMPK)-related kinase, leads to insulin hypersensitivity and resistance to diet-induced obesity. J Biol Chem (2012) 0.87
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
International network of cancer genome projects. Nature (2010) 20.35
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46